Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 3Recruiting 2Active not recruiting 2No longer available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Specimen Handling 218Magnetic Resonance Spectroscopy 196pembrolizumab 188Carboplatin 163Biopsy 130Cisplatin 129Nivolumab 121Paclitaxel 110Cyclophosphamide 107Radiotherapy 101Gemcitabine 96Dexamethasone 89durvalumab 85atezolizumab 71Rituximab 66Radiation 65Lenalidomide 64Doxorubicin 64Pemetrexed 61Bevacizumab 59Etoposide 56Docetaxel 55olaparib 53Ipilimumab 51Taxes 48Prednisone 48Fluorouracil 47venetoclax 46Cytarabine 46Vincristine 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × capmatinib × 90 days × Clear all
NCT05488314 2026-06-05

METalmark

Janssen Research & Development, LLC

Phase 1/2 Active not recruiting
57 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03040973 2026-04-02

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Novartis

Phase 2 Active not recruiting
29 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡